This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (7)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in JAMA  Topic Collections  • Substance Abuse/ Alcoholism  • Alert me on articles by topic  Social Bookmarking   What's this?

Henry R. Kranzler, MD

JAMA. 2000;284:1016-1017.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Since its approval by the Food and Drug Administration in 1949, the aversive agent disulfiram¹ was, for nearly 50 years, the only drug approved in the United States to treat alcohol dependence. However, in 1994, the Food and Drug Administration approved naltrexone, an opioid antagonist, for that indication based largely on the results of 2 federally funded studies.^2-3 The approval of naltrexone for alcoholism treatment has also increased interest on the part of the pharmaceutical industry in medications to treat alcohol dependence.

As a consequence of that increased interest, a number of compounds for alcoholism treatment are currently in clinical development in the United States. For example, acamprosate (calcium acetylhomotaurinate), an amino acid derivative that affects both -aminobutyric acid and excitatory amino acid (ie, glutamate) neurotransmission, has been studied in countries throughout Europe and is now in widespread clinical use there.⁴ Although the drug has not . . . [Full Text of this Article]

Author Affiliation: Alcohol Research Center, University of Connecticut School of Medicine, Farmington.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

Ondansetron for Reduction of Drinking Among Biologically Predisposed Alcoholic Patients: A Randomized Controlled Trial
Bankole A. Johnson, John D. Roache, Martin A. Javors, Carlo C. DiClemente, Claude Robert Cloninger, Thomas J. Prihoda, Patrick S. Bordnick, Nassima Ait-Daoud, and Julie Hensler
JAMA. 2000;284(8):963-971.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Invited Commentary * Serotonin transporter (SERT) brain density and neurobiological cloninger subtypes model: a lesson by human autoradiography studies
Leggio and Addolorato
Alcohol Alcohol 2008;43:148-150.
ABSTRACT | FULL TEXT  

Evidence-based treatments for alcohol dependence: new results and new questions.
Kranzler
JAMA 2006;295:2075-2076.
FULL TEXT